February 4, 2012
| Bio-IT World > Bio-IT Briefs


Bio-IT Briefs



Sigma-Aldrich announced the launch of Panorama Human Cancer Version 1 Protein Functional Microarray. Developed by Procognia Ltd, UK and licensed exclusively through Sigma-Aldrich, the Cancer V1 protein microarray contains 130 correctly folded proteins. These proteins are selected from a recent seminal scientific publication that reviewed and compiled all proteins that are implicated in mediating cancer. Read the press release.

Rensselaer Polytechnic Institute has been selected as one of six universities nationwide to be awarded a two-year, nearly $1 million planning grant from the National Institutes of Health (NIH) that will provide a foundation for the development of a center for cheminformatics research. The Rensselaer Exploratory Center for Cheminformatics Research (RECCR) will bring together an interdisciplinary research team to seek improved understanding of the relationships between chemical structure and function for use in biotechnology applications. Read the press release.

InforSense and Elsevier MDL have announced an expanded strategic relationship to integrate the new-generation MDL Isentris informatics platform and the InforSense KDE workflow-based integrative analytics platform, and to explore further joint development initiatives. The aim of the collaboration is to enable scientists in the life sciences to use information and knowledge more effectively in decision-making in order to enhance R&D productivity. Read the press release.

Tokyo-based Eisai Co., Ltd. and San Diego-based TorreyPines Therapeutics Inc. jointly announced the signing of a new research agreement that focuses on the discovery of genes responsible for late onset Alzheimer's disease. This latest agreement marks the continuation of Eisai's support for this program that began in 2001. A second collaboration agreement between TorreyPines and Eisai was signed in February of this year to support the discovery of small molecules that lower A-beta42, a peptide involved in the creation of amyloid plaques, a hallmark of Alzheimer's disease. Read the press release.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) this week launched a completely redesigned and enhanced website. The new site contains expanded information for prospective and current grantees and more patient-oriented information on technology-based medical procedures. The new web site can be viewed at: http://www.nibib.nih.gov.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .